Juan Ignacio Arraras1, Ana Manterola2, Jose Juan Illarramendi3, Gemma Asin4, Susana de la Cruz5, Berta Ibañez6, Arkaitz Galbete7, Esteban Salgado8, Uxue Zarandona9, Ruth Vera10, Miguel Angel Dominguez11, Enrique Martinez12. 1. Complejo Hospitalario de Navarra: Radiotherapeutic Oncology Department, Irunlarrea 3, 31008 Pamplona, Spain; Complejo Hospitalario de Navarra: Medical Oncology Department, Irunlarrea 3, 31008 Pamplona, Spain. Electronic address: jiarraras@correo.cop.es. 2. Complejo Hospitalario de Navarra: Radiotherapeutic Oncology Department, Irunlarrea 3, 31008 Pamplona, Spain. Electronic address: ana-manterola@hotmail.com. 3. Complejo Hospitalario de Navarra: Medical Oncology Department, Irunlarrea 3, 31008 Pamplona, Spain. Electronic address: jj.illarramendi.manas@cfnavarra.es. 4. Complejo Hospitalario de Navarra: Radiotherapeutic Oncology Department, Irunlarrea 3, 31008 Pamplona, Spain. Electronic address: gemma.asin.felipe@cfnavarra.es. 5. Complejo Hospitalario de Navarra: Medical Oncology Department, Irunlarrea 3, 31008 Pamplona, Spain. Electronic address: Susana.delacruz.sanchez@cfnavarra.es. 6. Navarrabiomed- Departamento de Salud-UPNA - REDISSEC, Methodology Unit, Pamplona, Spain. Electronic address: berta.ibanez.beroiz@navarra.es. 7. Navarrabiomed- Departamento de Salud-UPNA - REDISSEC, Methodology Unit, Pamplona, Spain. Electronic address: arkaitz.galbete.jimenez@cfnavarra.es. 8. Complejo Hospitalario de Navarra: Medical Oncology Department, Irunlarrea 3, 31008 Pamplona, Spain. Electronic address: Esteban.salgado.pascual@cfnavarra.es. 9. Complejo Hospitalario de Navarra: Radiotherapeutic Oncology Department, Irunlarrea 3, 31008 Pamplona, Spain; Complejo Hospitalario de Navarra: Medical Oncology Department, Irunlarrea 3, 31008 Pamplona, Spain. Electronic address: u.zaramendi@gmail.com. 10. Complejo Hospitalario de Navarra: Medical Oncology Department, Irunlarrea 3, 31008 Pamplona, Spain. Electronic address: ruth.vera.garcia@cfnavarra.es. 11. Complejo Hospitalario de Navarra: Radiotherapeutic Oncology Department, Irunlarrea 3, 31008 Pamplona, Spain. Electronic address: mdomingd@cfnavarra.es. 12. Complejo Hospitalario de Navarra: Radiotherapeutic Oncology Department, Irunlarrea 3, 31008 Pamplona, Spain. Electronic address: emartinl@cfnavarra.es.
Abstract
PURPOSE: This paper studies the Quality of Life (QL) of elderly early-stage breast cancer survivors. The aims are to compare the QL scores of these patients after follow-up with their scores before the start of radiotherapy (RT) and compare QL among different axillary treatment groups. METHODS: Of 173 patients over 65 who began treatment and completed the EORTC QLQ-C30 and QLQ-BR23 and the Interview for Deterioration in Daily Living Activities in Dementia (IDDD) before RT, 138 also completed these questionnaires three years after RT. Longitudinal changes in QL were assessed for the whole sample using linear mixed-effect models. Also assessed were differences in QL scores between axillary treatment groups (axillary node dissection ALND, sentinel lymph node biopsy SLNB, and no surgery) at the end of the follow-up (Anova or Kruskal-Wallis) and differences in the evolution of QL from baseline among these groups (linear regression models). RESULTS: QL scores in the follow-up were high (>70/100 points) in most QL areas, with moderate limitations (>30) in sexual functioning and enjoyment. Five areas (pain, nausea/vomiting, financial impact, breast symptoms and IDDD) improved significantly (<6 points) in the follow-up. The ALND group scored less for the future perspective item (15-20 points) in the follow-up than the other two axillary treatment groups. No differences between the pre-treatment and follow up assessments regarding treatment were found among the axillary treatment groups. CONCLUSIONS: Our results suggest that early-stage breast cancer patients adapted well both to their disease and treatments over the follow-up period and to the administration of RT. There were few QL differences between the axillary treatment groups.
PURPOSE: This paper studies the Quality of Life (QL) of elderly early-stage breast cancer survivors. The aims are to compare the QL scores of these patients after follow-up with their scores before the start of radiotherapy (RT) and compare QL among different axillary treatment groups. METHODS: Of 173 patients over 65 who began treatment and completed the EORTC QLQ-C30 and QLQ-BR23 and the Interview for Deterioration in Daily Living Activities in Dementia (IDDD) before RT, 138 also completed these questionnaires three years after RT. Longitudinal changes in QL were assessed for the whole sample using linear mixed-effect models. Also assessed were differences in QL scores between axillary treatment groups (axillary node dissection ALND, sentinel lymph node biopsy SLNB, and no surgery) at the end of the follow-up (Anova or Kruskal-Wallis) and differences in the evolution of QL from baseline among these groups (linear regression models). RESULTS: QL scores in the follow-up were high (>70/100 points) in most QL areas, with moderate limitations (>30) in sexual functioning and enjoyment. Five areas (pain, nausea/vomiting, financial impact, breast symptoms and IDDD) improved significantly (<6 points) in the follow-up. The ALND group scored less for the future perspective item (15-20 points) in the follow-up than the other two axillary treatment groups. No differences between the pre-treatment and follow up assessments regarding treatment were found among the axillary treatment groups. CONCLUSIONS: Our results suggest that early-stage breast cancerpatients adapted well both to their disease and treatments over the follow-up period and to the administration of RT. There were few QL differences between the axillary treatment groups.
Authors: Nadia A Nabulsi; Khatija W Naing; Huiwen Deng; Jenilee Cueto; Alemseged A Asfaw; Colin C Hubbard; Jifang Zhou; Inyoung Lee; Debanjali Mitra; Gregory S Calip; Ernest H Law Journal: J Patient Exp Date: 2022-07-11
Authors: S W M C Maass; L M Boerman; D Brandenbarg; P F M Verhaak; J H Maduro; G H de Bock; A J Berendsen Journal: Breast Date: 2020-09-30 Impact factor: 4.380